MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Amgen Inc

Slēgts

SektorsVeselības aprūpe

279.7 0.59

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

273.64

Max

281.65

Galvenie mērījumi

By Trading Economics

Ienākumi

-2.2B

627M

Pārdošana

586M

9.1B

P/E

Sektora vidējais

36.153

57.333

EPS

5.31

Dividenžu ienesīgums

3.43

Peļņas marža

6.901

Darbinieki

28,000

EBITDA

-517M

2.9B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+16.62% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.43%

2.63%

Nākamie ieņēmumi

2025. g. 1. maijs

Nākamais dividenžu datums

2025. g. 6. jūn.

Nākamais Ex dividenžu datums

2025. g. 16. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-6B

147B

Iepriekšējā atvēršanas cena

279.11

Iepriekšējā slēgšanas cena

279.7

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Amgen Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. febr. 21:29 UTC

Peļņas

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

2024. g. 30. okt. 20:18 UTC

Peļņas

Amgen Posts Higher 3Q Sales on Strong Demand

2025. g. 10. apr. 05:00 UTC

Peļņas

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 4. febr. 21:02 UTC

Peļņas

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Adj EPS $5.31 >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Rev $9.1B >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q EPS $1.16 >AMGN

2025. g. 4. febr. 21:01 UTC

Peļņas

Amgen 4Q Net $627M >AMGN

2025. g. 28. janv. 10:30 UTC

Top Ziņas

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2024. g. 27. dec. 07:00 UTC

Peļņas

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

2024. g. 23. dec. 15:04 UTC

Top Ziņas

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

2024. g. 13. dec. 14:53 UTC

Top Ziņas

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

2024. g. 30. nov. 12:00 UTC

Top Ziņas

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

2024. g. 26. nov. 12:34 UTC

Top Ziņas

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

2024. g. 4. nov. 12:00 UTC

Top Ziņas

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

2024. g. 30. okt. 20:02 UTC

Peļņas

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

2024. g. 30. okt. 20:02 UTC

Peļņas

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

2024. g. 30. okt. 20:02 UTC

Peļņas

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

2024. g. 30. okt. 20:02 UTC

Peļņas

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

2024. g. 30. okt. 20:02 UTC

Peļņas

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

2024. g. 30. okt. 20:01 UTC

Peļņas

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

2024. g. 30. okt. 20:01 UTC

Peļņas

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

Salīdzinājums

Cenas izmaiņa

Amgen Inc Prognoze

Cenas mērķis

By TipRanks

16.62% augšup

Prognoze 12 mēnešiem

Vidējais 326.36 USD  16.62%

Augstākais 389 USD

Zemākais 280 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Amgen Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

9

Pirkt

8

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

278.68 / 295.18Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.